Adverum Biotechnologies (ADVM) News Today $2.95 +0.07 (+2.43%) Closing price 04:00 PM EasternExtended Trading$2.96 +0.01 (+0.51%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Trexquant Investment LP Sells 77,303 Shares of Adverum Biotechnologies, Inc. $ADVMSeptember 13, 2025 | marketbeat.comAdverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comAdverum Biotechnologies (NASDAQ:ADVM) Stock Price Crosses Above 50-Day Moving Average - Here's WhySeptember 3, 2025 | marketbeat.comFY2025 Earnings Estimate for ADVM Issued By Chardan CapitalAugust 19, 2025 | marketbeat.comEquities Analysts Issue Forecasts for ADVM Q3 EarningsAugust 17, 2025 | marketbeat.comChardan Capital Reaffirms Buy Rating for Adverum Biotechnologies (NASDAQ:ADVM)August 15, 2025 | marketbeat.comAdverum Biotechnologies sees cash runway into 4Q25August 12, 2025 | msn.comAdverum Biotechnologies reports Q2 EPS ($2.34), consensus ($2.28)August 12, 2025 | msn.comAdverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline HighlightsAugust 12, 2025 | globenewswire.comAdverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 6, 2025 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Stake Boosted by BML Capital Management LLCJuly 26, 2025 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 25, 2025 | marketbeat.comReversal Of Fortune For Adverum Biotechnologies Insiders Who Made A US$526.8k PurchaseJuly 15, 2025 | finance.yahoo.comAdverum Biotechnologies, Inc. (ADVM) - Yahoo FinanceJuly 1, 2025 | finance.yahoo.comAdverum Biotechnologies price target lowered to $12 at MizuhoJune 26, 2025 | investing.comMizuho Has Lowered Expectations for Adverum Biotechnologies (NASDAQ:ADVM) Stock PriceJune 26, 2025 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Large Growth in Short InterestJune 18, 2025 | marketbeat.comAdverum Biotechnologies’ SWOT analysis: gene therapy stock faces pivotal yearJune 15, 2025 | investing.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Stock Holdings Boosted by Principia Wealth Advisory LLCJune 7, 2025 | marketbeat.comAdverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 5, 2025 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) CEO Sells $18,252.00 in StockMay 17, 2025 | insidertrades.comAdverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline HighlightsMay 14, 2025 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 12, 2025 | marketbeat.comAdverum Biotechnologies’ SWOT analysis: gene therapy firm faces pivotal yearMay 7, 2025 | uk.investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMMay 6, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMMay 5, 2025 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Bought by Renaissance Technologies LLCMay 5, 2025 | marketbeat.comAdverum Biotechnologies Grants Inducement Awards to New Employees Under 2017 Inducement PlanMay 4, 2025 | nasdaq.comAdverum Biotechnologies (ADVM) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comAdverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comTCG Crossover Management LLC Cuts Position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)May 1, 2025 | marketbeat.comAdverum Biotechnologies, Inc. (ADVM) Stock ForecastsApril 30, 2025 | ca.finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 29, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 28, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 25, 2025 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Purchases $149,000.00 in StockApril 25, 2025 | insidertrades.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 21, 2025 | globenewswire.comChardan Capital Has Lowered Expectations for Adverum Biotechnologies (NASDAQ:ADVM) Stock PriceApril 19, 2025 | marketbeat.comRoyal Bank of Canada Lowers Adverum Biotechnologies (NASDAQ:ADVM) Price Target to $5.00April 18, 2025 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Rating of "Moderate Buy" from AnalystsApril 18, 2025 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Given Buy Rating at HC WainwrightApril 18, 2025 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Releases Earnings ResultsApril 17, 2025 | marketbeat.comRBC Capital Keeps Their Hold Rating on Adverum Biotechnologies (ADVM)April 16, 2025 | markets.businessinsider.comAdverum Biotechnologies sees cash runway into 2H25April 15, 2025 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Adverum Biotechnologies (ADVM)April 15, 2025 | markets.businessinsider.comADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law FirmApril 15, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 14, 2025 | prnewswire.comADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. ...April 13, 2025 | gurufocus.com Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADVM Media Mentions By Week ADVM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADVM News Sentiment▼1.680.63▲Average Medical News Sentiment ADVM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADVM Articles This Week▼12▲ADVM Articles Average Week Get the Latest News and Ratings for ADVM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Adverum Biotechnologies and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies GALT News TVRD News NGNE News LFCR News MREO News ACB News RNAC News CADL News MNPR News NMRA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADVM) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
